Granted Patent B2

US 12,582,630 · App. 17/711,548 · Granted Mar 24, 2026

Inventors: Earnie Blackmon (Denver, CO); Tony Verzura (Denver, CO)

A61K31/353A61K31/352A61K36/3482

Abstract

Claims (29)

1 . A kit comprising at least one cannabinoid formulation, wherein the at least one formulation is selected from the group consisting of:

(a) a formulation wherein 95% or more of the total cannabinoids in the formulation is tetrahydrocannabinolic acid (THCa), cannabidiolic acid (CBDa) is less than 1%, cannabinolic acid (CBNa) is less than 3% and cannabichromenic acid (CBCa) is less than 1%;

(b) a formulation wherein 95% or more of the total cannabinoids in the formulation is tetrahydrocannabinol (THC), cannabidiol (CBD) is less than 1%, cannabinol (CBN) is less than 3% and cannabichromene (CBC) is less than 1%;

(c) a formulation wherein THCa is less than or equal to 35%, CBDa is greater than or equal to 60%, THC is less than 1%, CBN is less than 1% and CBC is less than 1%;

(d) a formulation wherein THCa is greater than or equal to 40%, CBDa is greater than or equal to 40%, THC is less than 1%, CBN is less than 1% and CBC is less than 1%;

(e) a formulation wherein THC is less than or equal to 35%, CBD is greater than or equal to 60%, CBN is less than 1%, and CBC is less than 1%;

(f) a formulation wherein THC is greater than or equal to 40%, CBD is greater than or equal to 40%, CBN is less than 1% and CBC is less than 1%; and

(g) a formulation wherein THC is less than or equal to 9%, CBD is greater than or equal to 40%, CBN is greater than or equal to 40% and CBC is less than 1%; and

wherein the cannabinoid formulation further comprises one or more terpene and/or flavonoid,

wherein the cannabinoid formulation is infused in a medium chain triglyceride (MCT).

2 . The kit of claim 1 , wherein the MCT is composed of any combination of C-6, C-8, C-10 and C-12 fatty acids.

3 . The kit of claim 1 , wherein two or more of the cannabinoid formulations are administered to relieve symptoms associated with anxiety, post-traumatic stress disorder, chronic pain, opiate dependency, paralysis, neuropathy, Crohn's disease, inflammatory bowel disorders, glaucoma, seizures, epilepsy, autism, or cancer.

4 . The kit of claim 1 , wherein the cannabinoid formulation is a liquid.

5 . The kit of claim 1 , wherein the terpene comprises β-myrcene, β-caryophyllene, or d-limonene.

6 . The kit of claim 1 , wherein the pH of the cannabinoid formulation is at least pH 8.0.

7 . A method of preparing a Cannabis extract comprising:

a. providing a Cannabis starting plant material comprising dried Cannabis flowers, flower rosin, hash rosin, hashish or kif, wherein the Cannabis flowers have a moisture content below 3%;

b. breaking apart or milling the Cannabis starting plant material;

c. combining the Cannabis starting plant material with a medium chain triglyceride (MCT) comprising NEOBEE 895 to produce a mixture;

d. heating the mixture for at least 3 hours to extract and infuse cannabinoids into the MCT; and

e. separating the Cannabis starting plant material and the MCT using a filter or silk screen to produce a Cannabis extract.

8 . The method of claim 7 , further comprising decarboxylating the phytocannabinoids prior to step (c).

9 . The method of claim 8 , wherein the decarboxylating comprises heating the Cannabis starting material at a temperature of about 221° F. for at least 15 minutes followed by heating at about 284° F. for at least 45 minutes.

10 . The method of claim 7 , further comprising heating the Cannabis extract at 284° F. for at about 45-74 minutes followed by heating at about 293° F. for at least about 55-90 minutes.

11 . The method of claim 7 , wherein the Cannabis plant material has been propagated from a single seed source or a tissue culture with specific ratios of cannabinoids.

12 . The method of claim 7 , wherein the Cannabis plant material is derived from a Cannabis strain having a minimum of 15% THC and less that 1% CBD.

13 . The method of claim 7 , wherein the Cannabis plant material is derived from Sour Tsunami×Catatonic, Sour Tsunami×Sour Tsunami, Sour Tsunami, Harlequin, R4, Swiss Gold, ACDC, CBD1, Sour Pineapple, or CBD Diesel.

14 . The method of claim 7 , wherein the Cannabis plant material is derived from Sour Tsunami×Catatonic, Sour Tsunami×Sour Tsunami, Sour Tsunami, Harlequin, R4 or ACDC strains.

15 . The method of claim 7 , wherein the Cannabis plant material is derived from CBD1, Sour Pineapple, CBD Diesel, Harlequin, ACDC or R4.

Assignments (3)

Continuity (1)

References Cited (155)